⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
JBIO News
Jade Biosciences, Inc. Common Stock
Jade Biosciences to Host Conference Call and Webcast on June 1, 2026, at 8:00 a.m. ET to Discuss Interim Phase 1 Healthy Volunteer Results for JADE101, a Novel, Potentially Best-in-Class Anti-APRIL Monoclonal Antibody in Development for IgA Nephropathy
globenewswire.com
JBIO
Jade Biosciences Announces First Participant Dosed in First-in-Human Phase 1 Clinical Trial of JADE201, a Novel Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody
globenewswire.com
JBIO
Jade Biosciences Announces First Participant Dosed in Phase 2 JUNIPER Clinical Trial of JADE101 in IgA Nephropathy
globenewswire.com
JBIO
Form 8-K
sec.gov
JBIO
Jade Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Update
globenewswire.com
JBIO
Jade Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
JBIO
Form 8-K
sec.gov
JBIO
Jade Biosciences Appoints Edward R. Conner, M.D., as Chief Medical Officer
globenewswire.com
JBIO
ASTL
Form 8-K
sec.gov
JBIO
Form 8-K
sec.gov
JBIO